A 58-year-old woman with alcoholic cirrhosis (Child–Pugh B) presents with progressive abdominal distension, weight gain of 3 kg in 2 weeks, and ankle oedema. On examination, she has ascites, hepatomegaly, and no signs of spontaneous bacterial peritonitis (SBP). Serum sodium is 128 mEq/L, and her urine sodium is 5 mEq/L. She is currently on spironolactone 100 mg daily. What is the most appropriate next step in management?

Explanation

## Management of Refractory Ascites in Cirrhosis ### Clinical Assessment **Key Point:** This patient has: - **Ascites** with recent weight gain (3 kg in 2 weeks) — indicates fluid retention - **Hyponatraemia** (Na^+^ 128 mEq/L) — suggests SIADH or dilutional hyponatraemia from cirrhosis - **Low urine sodium** (5 mEq/L) — indicates avid renal sodium retention (prerenal state) - **No SBP** — peritonitis excluded - **Inadequate diuretic response** on monotherapy — suggests need for combination therapy This is **refractory ascites** (ascites not responding to standard diuretic dosing). ### Classification of Ascites Response | Type | Definition | Management | |------|-----------|------------| | **Responsive** | Resolves with diuretics ≤160 mg spironolactone + ≤40 mg furosemide | Continue diuretics, dietary sodium restriction | | **Partially responsive** | Partial improvement but not complete resolution | Increase diuretics to maximum tolerated doses | | **Refractory** | No response despite maximum diuretics (spironolactone 400 mg + furosemide 160 mg) | LVPA + albumin, TIPS, liver transplant | ### Stepwise Diuretic Escalation **High-Yield:** The standard approach is: 1. **First-line:** Spironolactone (aldosterone antagonist) — start 100 mg daily - Increases to 200, 300, 400 mg daily at 3–7 day intervals - Ratio: spironolactone:furosemide = 100:40 2. **Add loop diuretic** when spironolactone alone is insufficient: - Furosemide 40 mg daily, increase to 80, 120, 160 mg daily - Maintain ratio of 100:40 (e.g., spironolactone 200 + furosemide 80) 3. **Monitor:** - Weight loss: target 0.5–1 kg/day (slower if no peripheral oedema) - Serum creatinine, potassium, sodium - Stop if creatinine rises >50% or K^+^ >6 mEq/L ### Why This Patient Needs Combination Therapy This patient is on **monotherapy (spironolactone 100 mg alone)** and has: - Ongoing ascites accumulation - Hyponatraemia (dilutional) - Avid sodium retention (urine Na 5 mEq/L) **Clinical Pearl:** Monotherapy is often insufficient. Adding a loop diuretic synergistically blocks sodium reabsorption at different nephron sites (distal tubule + loop of Henle), improving efficacy. ### Correct Management Sequence ```mermaid flowchart TD A[Ascites + inadequate response to monotherapy]:::outcome --> B[Increase spironolactone to 200 mg]:::action B --> C[Add furosemide 40 mg daily]:::action C --> D[Assess response at 7 days]:::decision D -->|Improving| E[Continue, monitor K+, Na+, Cr]:::action D -->|Not improving| F[Increase both drugs further]:::action F --> G{Maximum doses reached?}:::decision G -->|Yes| H[LVPA + albumin or TIPS]:::action G -->|No| F ``` ### Why Not the Other Options? **Fluid restriction (500 mL/day):** - Worsens hyponatraemia by increasing osmolarity mismatch - Should be reserved for severe hyponatraemia (Na^+^ <120 mEq/L) or SIADH - This patient's hyponatraemia is dilutional (from ascites), not SIADH - Diuretics are more effective than fluid restriction **Large-volume paracentesis (LVPA):** - Indicated for **tense ascites** (respiratory compromise, abdominal pain) or **refractory ascites** (failure of maximum diuretics) - This patient has not yet reached maximum diuretic dosing - LVPA is premature and increases infection risk **Tolvaptan (vasopressin antagonist):** - Expensive, not first-line in India - Reserved for severe hyponatraemia with SIADH (Na^+^ <120 mEq/L) - This patient's hyponatraemia is dilutional, not SIADH - Sodium restriction to 500 mg/day is too aggressive and worsens hyponatraemia **Mnemonic:** **SALT** — Spironolactone first, Add loop diuretic, Limit sodium intake, TIPS/LVPA if refractory. [cite:Harrison 21e Ch 297]